Treatment
Carboplatin clinical trials
We’re tracking 493 recruiting studies that include Carboplatin, each written for real people, not researchers, below.
Recruiting studies
- NCT06318897RecruitingPhase 2
Immunotherapy with chemo for early triple-negative breast cancer
This trial tests a combination of an immunotherapy drug (pembrolizumab) plus two chemotherapy drugs (carboplatin and paclitaxel) given before surgery for people with early-stage, triple-negative breast cancer. The goal is to see if this treatment helps shrink or eliminate the tumor before it's removed.
Houston, TexasAges 18 years+ - NCT04954599RecruitingPhase 1/Phase 2
CP-506 for hard-to-treat cancers with DNA repair defects
This Phase 1/2 study tests CP-506 in people with advanced solid tumors that have specific DNA repair problems (homologous recombination or Fanconi anemia-related defects). It may be used alone or combined with carboplatin or an immune therapy, aiming to shrink tumors or improve control when standard options are limited.
BrusselsAges 18 years+ - NCT06085729RecruitingPhase 1/Phase 2
Study of ADI-PEG20 with chemo for aggressive prostate cancer
This study tests a combination of three drugs—ADI-PEG20, carboplatin, and cabazitaxel—in men with aggressive variant prostate cancer that has stopped responding to hormone therapy. The goal is to see if this combination can shrink or slow the cancer.
Houston, TexasAges 18 years+ - NCT05942300RecruitingPhase 1
CPI-0209 plus platinum chemo for recurring ovarian cancer
This Phase 1 trial tests CPI-0209 combined with the standard platinum chemotherapy approach in people whose ovarian (or related) cancer has returned after prior platinum treatment. The goal is to find a safe dose and see whether this combination can help keep the cancer under control.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05902169RecruitingPhase 3
Ultrasound with carboplatin for recurrent glioblastoma
This trial tests a device that opens the blood-brain barrier using ultrasound, allowing chemotherapy to reach the brain tumor better. It compares this approach to standard chemotherapy for people whose glioblastoma has returned.
Phoenix, ArizonaAges 18 years+ - NCT04681417RecruitingPhase 2/Phase 3
Eye-sparing treatment options for children with retinoblastoma
This trial studies whether newer “save-the-eye” treatment plans can control retinoblastoma (eye cancer) while keeping vision as good as possible. It compares different conservative treatment strategies depending on how the tumor looks and where it is.
Saint-Denis, La RéunionAges 6 months–6 years - NCT05806515RecruitingPhase 2
Carboplatin before surgery for high-risk BRCA prostate cancer
This trial tests giving the chemotherapy drug carboplatin before surgery to treat people with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene change. The goal is to shrink or control the cancer before an operation and improve outcomes.
Anchorage, AlaskaAges 18 years+ - NCT04722978RecruitingPhase 3
Chemo plus moxifloxacin for metastatic triple-negative breast cancer
This trial tests whether adding moxifloxacin (an antibiotic) to standard chemotherapy helps people with metastatic triple-negative breast cancer live longer or respond better. You may qualify if your cancer has the right lab markers and you haven’t had treatment for metastatic disease yet.
Guangzhou, GuangdongAges 18–70 - NCT05456256RecruitingPhase 2
LP-300 plus chemo for lung cancer in never-smokers
This Phase 2 trial tests LP-300 with carboplatin and pemetrexed to treat advanced lung adenocarcinoma in people who have never smoked. It may help shrink tumors and slow the disease in a specific genetic group of lung cancer.
Beverly Hills, CaliforniaAges 18 years+ - NCT05431270RecruitingPhase 1/Phase 2
Test drug that targets CD73, alone or with immunotherapy
This early-stage study tests mavrostobart (an anti-CD73 antibody) to see what dose is safe and whether it can help shrink tumors. It’s studied by itself and also with a PD-1 immune therapy or chemotherapy, depending on your cancer type and prior treatments.
Huntersville, North CarolinaAges 18 years+ - NCT05385861Enrolling by invitationPhase 1/Phase 2
ONIVYDE plus carboplatin for advanced gut neuroendocrine cancer
This Phase 1/2 study tests ONIVYDE® (a type of irinotecan drug) combined with carboplatin in people with advanced or metastatic gastroenteropancreatic poorly differentiated neuroendocrine carcinoma. The goal is to see how well the treatment works and how safely it can be given.
Kaohsiung CityAges 20–80 - NCT02734069Recruiting
Testing whether muscle mass affects carboplatin side effects
This study looks at how your body’s “fat-free mass” (mostly muscle and organs) may change the dose of carboplatin and the risk of chemotherapy side effects. It’s for people with advanced lung cancer who are starting treatment with carboplatin plus paclitaxel for the first time.
Mexico CityAges 18 years+ - NCT05019716RecruitingPhase 1/Phase 2
Adding ZEN003694 to chemo for NUT cancer
This early-phase study tests whether adding ZEN003694 to standard chemotherapy (cisplatin/etoposide or carboplatin/paclitaxel) is safe and can help control NUT carcinoma. It enrolls people ages 12–17 and adults, including some patients whose cancer has spread or can’t be safely removed.
Los Angeles, CaliforniaAges 12 years+ - NCT04478292RecruitingPhase 3
New treatment strategy for children with newly diagnosed liver cancer
This Phase 3 study tests a modified treatment plan for children newly diagnosed with hepatoblastoma, a type of liver cancer. It may help improve how well treatment works and how safely it can be given by using a structured approach.
Shanghai, Shanghai MunicipalityAges Up to 18 years - NCT04339218RecruitingPhase 3
Cryoablation plus pembrolizumab and chemotherapy for lung cancer spread
This trial studies whether freezing a small number of lung cancer spots (cryoablation) alongside standard immunotherapy (pembrolizumab) and chemotherapy can improve outcomes in people with metastatic lung adenocarcinoma. It’s meant for people who have measurable tumors that can be safely targeted with the freezing treatment.
Bordeaux, GirondeAges 18 years+ - NCT04332367RecruitingPhase 2
New chemo plus ramucirumab for lung cancer after maintenance
This Phase 2 trial studies a combination of chemotherapy (carboplatin and a “taxane”) plus ramucirumab for people with advanced lung cancer that came back or progressed after prior maintenance treatment. It may help by attacking cancer growth after earlier therapy no longer worked.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04166409RecruitingPhase 3
Selumetinib versus chemo for low-grade brain tumor in children
This trial studies whether the targeted drug selumetinib works better than standard chemotherapy (carboplatin and vincristine) for children and young adults with a specific type of low-grade glioma (grade 1 or 2). It may help shrink tumors and slow growth while comparing side effects between the two treatment approaches.
Birmingham, AlabamaAges 2–21 - NCT04198766RecruitingPhase 1/Phase 2
New OX40 immunotherapy for advanced solid tumors
This trial tests a new immunotherapy drug (INBRX-106) alone or with Keytruda (pembrolizumab) for adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help the immune system fight cancer.
Duarte, CaliforniaAges 18 years+ - NCT04038502RecruitingPhase 2
Comparing carboplatin and olaparib for prostate cancer with BRCA gene changes
This study compares two treatments for prostate cancer that has spread and has specific gene changes (BRCA or related genes). It aims to see which treatment works better for people whose cancer has stopped responding to other hormone therapies.
West Los Angeles, CaliforniaAges 18 years+ - NCT03872661RecruitingPhase 2
New lung cancer medicines before surgery for unresectable stage III
This Phase 2 trial tests a combination of IBI308 plus bevacizumab and pemetrexed/carboplatin given before surgery, aiming to shrink or control unresectable stage III non-small cell lung cancer. It may help some people become eligible for surgery and improve outcomes, while also testing safety and effectiveness.
Guangzhou, GuangdongAges 18–75 - NCT03522064RecruitingPhase 2
HRD-positive advanced prostate cancer trial with androgen therapy and chemo
This Phase 2 study tests whether blocking male hormones (androgen therapy) plus the chemotherapy drug carboplatin can shrink advanced prostate cancer in men with specific DNA repair problems. It is for cases where prostate-specific antigen (PSA) is rising even though testosterone is already kept very low.
Sydney, New South WalesAges 18 years+ - NCT03067181RecruitingPhase 3
Active surveillance and chemotherapy for germ cell tumors
This study looks at how to manage germ cell tumors in children and young adults using careful monitoring for some patients and chemotherapy for others. It aims to see whether these approaches can control the cancer while avoiding unnecessary treatment when possible.
Birmingham, AlabamaAges Any age - NCT06466382Recruiting
Personalized cancer therapy for advanced ovarian cancer
This trial tests whether a treatment plan tailored to your specific tumor and health can work better for advanced ovarian, peritoneal, or fallopian tube cancer. It aims to find the best therapy for each patient to improve outcomes.
Baden, Canton of AargauAges 18 years+ - NCT07744126RecruitingPhase 2
Combination drug therapy for head and neck cancer that has spread
This trial tests a new combination of two drugs (telisotuzumab adizutecan and pembrolizumab) for people with head and neck cancer that has come back or spread and cannot be cured with local treatments. The goal is to see if this combination can help control the cancer and to find the best dose.
Duarte, CaliforniaAges 18 years+
Common questions
- Are there clinical trials studying Carboplatin?
- Yes. Clin2 currently lists 493 recruiting studies that include Carboplatin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Carboplatin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Carboplatin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Carboplatin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.